OMNIAB, INC. Revenue
OMNIAB, INC. (OABI) reported Revenue of $13.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $13.41M, a 244.24% increase year-over-year.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $14.43M, a 247.30% increase year-over-year.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $8.38M, a 22.47% decline year-over-year.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.24M, a 46.33% decline year-over-year.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $18.67M, a 29.27% decline from fiscal 2024.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $26.39M, a 22.75% decline from fiscal 2023.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $34.16M, a 42.17% decline from fiscal 2022.
- OMNIAB, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $59.08M, a 70.02% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.41M 10-Q · filed 2026-08-06 | $27.84M 10-Q · filed 2026-08-06 | $36.22M derived: sum of 3 quarters · filed 2026-08-06 | $38.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.43M 10-Q · filed 2026-05-07 | $22.80M derived: sum of 2 quarters · filed 2026-05-07 | $25.04M derived: sum of 3 quarters · filed 2026-05-07 | $28.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $10.62M derived: sum of 2 quarters · filed 2026-03-04 | $14.51M derived: sum of 3 quarters · filed 2026-08-06 | $18.67M 10-K · filed 2026-03-04 |
| 2025-09-30 | $2.24M 10-Q · filed 2025-11-04 | $6.14M derived: sum of 2 quarters · filed 2026-08-06 | $10.29M 10-Q · filed 2025-11-04 | $21.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.90M 10-Q · filed 2026-08-06 | $8.05M 10-Q · filed 2026-08-06 | $18.86M derived: sum of 3 quarters · filed 2026-08-06 | $23.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.15M 10-Q · filed 2026-05-07 | $14.96M derived: sum of 2 quarters · filed 2026-05-07 | $19.13M derived: sum of 3 quarters · filed 2026-05-07 | $26.74M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $14.98M derived: sum of 2 quarters · filed 2026-03-04 | $22.59M derived: sum of 3 quarters · filed 2026-03-04 | $26.39M 10-K · filed 2026-03-04 |
| 2024-09-30 | $4.17M 10-Q · filed 2025-11-04 | $11.79M derived: sum of 2 quarters · filed 2025-11-04 | $15.59M 10-Q · filed 2025-11-04 | $20.41M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $7.61M 10-Q · filed 2025-08-06 | $11.41M 10-Q · filed 2025-08-06 | $16.24M derived: sum of 3 quarters · filed 2025-08-06 | $21.71M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $3.80M 10-Q · filed 2025-05-08 | $8.62M derived: sum of 2 quarters · filed 2025-05-08 | $14.10M derived: sum of 3 quarters · filed 2025-05-08 | $21.05M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $10.30M derived: sum of 2 quarters · filed 2025-03-18 | $17.25M derived: sum of 3 quarters · filed 2025-03-18 | $34.16M 10-K · filed 2025-03-18 |
| 2023-09-30 | $5.48M 10-Q · filed 2024-11-12 | $12.42M derived: sum of 2 quarters · filed 2024-11-12 | $29.34M 10-Q · filed 2024-11-12 | $64.69M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $6.95M 10-Q · filed 2024-08-08 | $23.86M 10-Q · filed 2024-08-08 | $59.21M derived: sum of 3 quarters · filed 2024-08-08 | $66.12M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $16.92M 10-Q · filed 2024-05-09 | $52.26M derived: sum of 2 quarters · filed 2024-05-09 | $59.17M derived: sum of 3 quarters · filed 2024-05-09 | $66.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $35.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $42.26M derived: sum of 2 quarters · filed 2024-03-25 | $49.45M derived: sum of 3 quarters · filed 2024-03-25 | $59.08M 10-K · filed 2024-03-25 |
| 2022-09-30 | $6.91M 10-Q · filed 2023-11-09 | $14.11M derived: sum of 2 quarters · filed 2023-11-09 | $23.73M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $7.20M 10-Q · filed 2023-08-10 | $16.82M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $9.62M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $34.75M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |